• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Screening Data Exchange Standards
 

Screening Data Exchange Standards

on

  • 613 views

David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.

David Kniaz (Merck) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session at the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.

Statistics

Views

Total Views
613
Views on SlideShare
613
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Screening Data Exchange Standards Screening Data Exchange Standards Presentation Transcript

    • Standards for Exchanging Screening Data Dave Kniaz Merck Research IT, Discovery Pre-Clinical Sciences Director, Business Architecture Pistoia Conference, April 24, 2012http://pistoiaalliance.org
    • Problem StatementGeneral Introduction (Pistoia Hanover Germany Workshop):Declining R&D productivity, rising costs of commercialization & shorterexclusivity period have driven up the average cost of launching a successfulnew drug to US $ 1.7 billion. To facilitate drug development & to lower thecost & risk of launching new drugs on their own, pharmaceutical companieshave increasingly turned to alliances for outsourcing.Screening Data / Exchange CollaborationTo respond to this challenge, large life science organizations are contributingto virtualization / externalization of R&D via various types of partnershipsbetween organizations including but not limited to outsourcing and co-sourcing assays to CROs. No standards currently exist which supportexchange of screening data within and between organizations impactingcollaboration capabilities and corresponding impacting discovery projectcycle time, cost and efficiency. 2
    • Proposal and Value PropositionProposalDevise standards including but not limited to definingcommon assay result data formats and data definitions for“routine” primary, secondary in vitro pharmacology assaysgenerally outsourced by large pharmas to CROs.Value PropositionReduce discovery project hit to lead cycle time at reducedcost with improved data quality by reducing the need todevelop one off methods to exchange screening data.
    • Discussion Points• Proposed starting point to select specific low IP risk discovery in vitro pharmacology assays most large pharmas outsource• Consider partnership with Society for Laboratory Automation and Screening• Leverage and extend existing standards• Start with large pharma representatives and add CRO representatives and software vendors as project progresses.Subject Matter expert resources are needed to required to work with resources Pistoia is committing to define use case scenarios and business case required to prepare a project proposal.